Full Press Release Details
Announces the Commencement of Direct Trading on NASDAQ
DUBLIN--(BUSINESS WIRE)--February 5, 2013--ICON plc, (NASDAQ: ICLR)
(ISIN:IE0005711209), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, commenced direct trading of ICON ordinary shares on NASDAQ
(CUSIP Number G4705A 100) yesterday, 4th February 2013. This
follows ICON's withdrawal from the Irish Stock Exchange on the 30th
January 2013 and the termination of the ADR programme in accordance with
the resolutions approved by the shareholders at the Extraordinary
General Meeting of the Company on 17th December 2012.
The information contained in this release is as of 5th
February 2013. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to ICON
and its business can be found in ICON's Annual Report for the fiscal
year ended December 31, 2011 and in the forms filed with the US
Securities and Exchange Commission, including the Forms 20-F, F-1, S-8
and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 82 locations in 40 countries and has
approximately 9,430 employees. Further information is available at http://www.iconplc.com.
Chief Financial Officer
VP Investor Relations